Sildenafil in Heart Failure With Reactive Pulmonary Hypertension

• Status: Terminated
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Sildenafil 20mg taken three times a day is effective in the treatment of Heart Failure with Reactive Pulmonary Hypertension. This is a double-blind, placebo controlled trial.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Maya Guglin; University of Kentucky
• Treatments: Sildenafil Citrate

Criteria

Inclusion Criteria:

• Known chronic heart failure appropriately treated with Angiotensin converting enzyme (ACE) inhibitors and beta blockers, unless contraindicated or poorly tolerated

• indication for right heart catheterization

• pulmonary artery mean pressure >25 mmHg

• pulmonary capillary wedge pressure > 15 mmHg

• pulmonary vascular resistance > 3 Wood units

Exclusion Criteria:

• hypersensitivity, allergy, or intolerable side effect to sildenafil

• history of primary pulmonary hypertension, connective tissue disorder, severe chronic obstructive pulmonary disorder (COPD), pulmonary embolism, or left to right shunt

• co-morbidities, limited exercise intolerance:

• morbid obesity (BMI >40)

• COPD with oxygen dependence

• severe peripheral vascular disease with intermittent claudication

• status post amputation of lower extremity at any level

• severe degenerative joint disease preventing normal walking